Aston Villa Football Club Announces New Team Store in Birmingham's Iconic Bullring
BIRMINGHAM, England--(BUSINESS WIRE)--Feb 13, 2025--
Aston Villa Football Club continues its rapid growth trajectory both on and off the pitch, further expanding its commercial footprint with the launch of a brand-new retail store in the heart of Birmingham's iconic Bullring shopping centre. The Aston Villa Bullring store is scheduled to open in May 2025.
Spanning 10,000 square feet across a ground and mezzanine floor, the store will showcase Aston Villa's full retail offering, including home, away, and third kits, training wear, lifestyle collections, and exclusive limited-edition releases. Additionally, it will feature a significant adidas collection, spanning footwear and apparel across running, training, football, Originals, women's, and kids' ranges.
The store's design takes inspiration from Aston Villa's rich 150-year history, incorporating cultural touchpoints from Villa Park while integrating a museum section that celebrates the club's deep-rooted connection to both Birmingham and football history. A nod to the iconic Holte End will be woven into the space, reflecting the passion and tradition of Villa's fanbase.
Aston Villa is also introducing 'Aston Works,' an area dedicated to product personalisation, allowing fans to customise their purchases with bespoke designs. This initiative underscores the club's commitment to creating a truly immersive and interactive shopping experience.
' As Aston Villa continues to drive ambitious commercial growth, we are excited to announce this fantastic new store, in an iconic retail location,' said David Asquith, Vice President Retail at Aston Villa. 'Retail continues to play a pivotal role in the strategic vision for Aston Villa, reinforcing the club's ability to comply with stringent Premier League regulations while solidifying our stature as a World-class organisation capable of continually competing and winning at the highest level. The Bullring store represents a major step in that journey, offering fans and sports enthusiasts a dynamic shopping experience that seamlessly combines sport, lifestyle, and club heritage.'
Conveniently situated in the Bullring—next door to Selfridges and alongside premium retailers such as Sephora—the store is set to become a must-visit destination for both supporters and general shoppers. Its prime location strengthens Aston Villa's presence in Birmingham city centre, reinforcing the club's ambition to position itself among the elite in both English and European football.
As a proud employer committed to equality and diversity, Aston Villa will ensure the store upholds these values, creating an inclusive and welcoming environment for all staff and visitors.
About Aston Villa Football Club
Founded in 1874, Aston Villa Football Club is a founding member of the Football League and a leading institution in the English game. One of only five English clubs to have been crowned champions of Europe, the team has historically enjoyed exceptional success domestically, including seven First Division Championships, seven FA Cup titles, and five Football League Cups.
A club of the future, AVFC is committed to innovating technologically, on and off the pitch, providing best in-class experience for fans and leading the football industry for best practice. United behind the club values of Pride, Passion and Purpose, Aston Villa Football Club continually thrives to push the boundaries of what a football club should be.
Communications Director, AVFC
KEYWORD: UNITED KINGDOM EUROPE
SOURCE: Aston Villa Football Club
Copyright Business Wire 2025.
PUB: 02/13/2025 09:41 AM/DISC: 02/13/2025 09:42 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
33 minutes ago
- Business Insider
NDAE Exchange Unveils NDAE Academy 2.0 for Crypto Learning Advancement
Denver, Colorado, June 23rd, 2025, FinanceWire NDAE Exchange announced the launch of NDAE Academy 2.0, its enhanced educational platform designed to equip users with practical knowledge and guided tools for mastering digital assets. With tiered courses, AI-powered assistants, and hands-on simulations, the platform aims to serve both newcomers and experienced traders in the rapidly evolving crypto space. As demand for reliable blockchain education rises, NDAE Academy 2.0 offers a structured learning experience covering custody, DeFi strategies, smart contract interaction, and compliance fundamentals. The initiative reflects NDAE's long-term strategy to pair trading tools with user empowerment. 'We see education as foundational infrastructure in a decentralized world, not a luxury add-on,' said Angela Brooks, Director of Educational Strategy at NDAE Exchange. 'NDAE Academy 2.0 ensures our users grow with the industry—not behind it.' Highlights of NDAE Academy 2.0 include: Tiered Curriculum Structure: Courses are categorized into foundational, intermediate, and strategic levels, auto-recommended based on user behavior. AI Learning Assistant: Learners receive real-time guidance, summaries, and answers through an embedded AI module tailored to their progress. Simulation Mode: Users can practice mock trades, DeFi staking, and smart contract interactions in a no-risk environment. Blockchain-Verified Certification: Upon completing key modules, learners earn verifiable certificates to demonstrate functional expertise. Live Content Sync: The curriculum is continuously updated through NDAE's internal research and market insights team to reflect the latest developments in crypto and Web3. The 2.0 platform is now live in five languages—English, Mandarin Chinese, Spanish, Korean, and Turkish—with more in development. Access is free for all NDAE Exchange registered users. By reinforcing education as a core pillar of the platform, NDAE Exchange affirms its mission to not only build the future of digital trading—but also the knowledge base required to navigate it confidently. About NDAE Exchange NDAE Exchange is a U.S.-based global digital asset trading platform focused on AI-driven infrastructure, institutional-grade security, and multi-jurisdictional compliance. NDAE serves users across more than 100 countries and offers a wide range of crypto products, including spot trading, DeFi access, risk-managed tools, and investor education. The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended that users practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Contact PR Manager
Business Wire
33 minutes ago
- Business Wire
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the following link: The event and accompanying slides can also be accessed by visiting the investor relations section of the company's website at An archived webcast will be available on the company's website following the event. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge (GC) induced symptoms. FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099). The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035). Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects. The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo. Gluten challenge induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain and abdominal bloating) reported during the 16 day gluten challenge from patient diaries/AE collection demonstrated a 42% benefit for FB102 treated subject (4.0 events per subject) compared to placebo (6.9 events per subject). There were no dropouts in the study. Treatment emergent adverse events (TEAE) were primarily mild (grade 1) with no grade 3 or higher SAEs reported in the FB102 arm. 'We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team. Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study. The Phase 2 celiac disease study is initiating with a topline readout expected in 2026.' said Paul Wagner, Ph.D. CEO and Chairperson of Forte Biosciences. 'These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes. We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026.' About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward-Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding Forte's beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102, the expected timeline for the Phase 2 celiac study and related readout, and the expected timing of topline results for the FB102 vitiligo study. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte's ability to obtain sufficient additional capital to continue to advance Forte's product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte's product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials; the risk that results from preclinical and the Phase 1b trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte's business and operating results is contained in Forte's Quarterly Report on Forms 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc.
Business Wire
an hour ago
- Business Wire
NPK Announces New $150 Million Revolving Credit Facility
THE WOODLANDS, Texas--(BUSINESS WIRE)--NPK International Inc. (NYSE: NPKI) ('NPK' or the 'Company') today announced that it has entered into a new credit agreement ('Agreement') effective June 20, 2025, which includes a $150 million revolving loan facility, replacing the Company's previous asset-based revolving credit facility. The Agreement has a term of five years and also includes an accordion feature, allowing for the expansion of the revolving loan facility up to $250 million. Under the terms of the Agreement, revolving loans bear interest at either Term SOFR plus 175 to 225 basis points or the Base Rate plus 75 to 125 basis points, with the applicable margin determined based on the Company's consolidated leverage ratio, as calculated in accordance with the Agreement. The bank group participating in the facility includes Bank of America, N.A., Amegy Bank, Regions Bank, First Horizon Bank, Texas Capital Bank and Woodforest National Bank. Gregg Piontek, NPK's Senior Vice President and Chief Financial Officer, stated, "We are very pleased to have the support of our bank group, including our long-term partners, as well as new partnerships established through this Agreement. The new facility provides expanded liquidity and improved flexibility, better enabling us to execute on our long-term growth strategy and capital allocation priorities, consistent with our focus on driving long-term value creation for our shareholders." For further information regarding the Agreement, please refer to the Company's Current Report on Form 8-K, to be filed with the Securities and Exchange Commission on or before June 26, 2025. ABOUT NPK INTERNATIONAL NPK International Inc. is a worksite access solutions company that manufactures, sells, and rents industry-leading sustainable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The Company delivers superior quality and reliability across critical infrastructure markets, including electrical transmission & distribution, oil and gas exploration, pipeline, renewable energy, petrochemical, construction, and other industries. For more information, visit our website at FORWARD-LOOKING STATEMENTS This news release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical facts are forward-looking statements. Words such as 'will,' 'may,' 'could,' 'would,' 'should,' 'anticipates,' 'believes,' 'estimates,' 'expects,' 'plans,' 'intends,' 'guidance,' and similar expressions are intended to identify these forward-looking statements but are not the exclusive means of identifying them. These statements are not guarantees that our expectations will prove to be correct and involve a number of risks, uncertainties, and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by NPK, particularly its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q, as well as others, could cause actual plans or results to differ materially from those expressed in, or implied by, these statements. These risk factors include, but are not limited to, risks related to our sale of the Fluids Systems business; our ability to generate organic growth; economic and market conditions that may impact our customers' future spending; the effective management of our fleet, including our ability to properly manufacture, safeguard, and maintain our fleet; international operations; operating hazards present in our and our customers' industries and substantial liability claims; our contracts that can be terminated or downsized by our customers without penalty; our product offering and market expansion; our ability to attract, retain, and develop qualified leaders, key employees, and skilled personnel; expanding our services in the utilities sector, which may require unionized labor; the price and availability of raw materials; inflation; capital investments and business acquisitions; market competition; technological developments and intellectual property; severe weather, natural disasters, and seasonality; public health crises, epidemics, and pandemics; our cost and continued availability of borrowed funds, including noncompliance with debt covenants; environmental laws and regulations; legal compliance; the inherent limitations of insurance coverage; income taxes; cybersecurity incidents or business system disruptions; activist stockholders that may attempt to effect changes at our Company or acquire control over our Company; share repurchases; and our amended and restated bylaws, which could limit our stockholders' ability to obtain what such stockholders believe to be a favorable judicial forum for disputes with us or our directors, officers or other employees. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities laws. NPK's filings with the Securities and Exchange Commission can be obtained at no charge at as well as through our website at
